Compare Davita Inc (DVA) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Davita Inc trades at $178.35 (market cap $11.72B), while Virgin Galactic Holdings, Inc. trades at $3.33 (market cap $488.94M). The key difference: Davita Inc is far larger — about 24× Virgin Galactic Holdings, Inc.'s market cap, and Davita Inc is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| DVA | SPCE | |
|---|---|---|
Market Cap | $11.72B | $488.94M |
Sector | Health | Industrials |
52-Week High | $240.96 | $7.52 |
52-Week Low | $103.87 | $2.17 |
Enterprise Value | $24.44B | $588.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
SPCE trades at $3.10, up 5.8% in the last session, with a bullish technical signal from moving averages but an overbought RSI. The company continues to post significant losses, with a net income margin of -19,781.3% in 2025, though it has beaten EPS estimates for the last three quarters. Cash flow remains negative, but the trend is improving, with net cash flow narrowing to -$35.17 million in 2025 from -$207 million in 2022. Recent news highlights sector volatility and an upcoming Q2 2026 earnings report on August 12, 2026.
The outlook is highly speculative, with substantial execution risks and cash burn offset by potential in the nascent space tourism market. Analyst consensus is mixed, with 29% buy ratings. Investors face high volatility and operational challenges, making it suitable only for risk-tolerant portfolios seeking long-term growth in a disruptive industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
